Dimerix

Dimerix P/B

The P/B (Price-to-Book Ratio) of Dimerix (DXB.AX) as of Oct 19, 2026 is -20.14. In the previous year, P/B (Price-to-Book Ratio) was 22.21 — a change of -190.67% (lower).

P/B

-20.14

YoY

-190.67%

Last updated:

P/B (Price-to-Book Ratio) of Dimerix is 2026 -20.14 . P/B (Price-to-Book Ratio) of Dimerix was 2025 22.21 . It decreases by -190.67% lower compared to the previous year.

The Dimerix P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
70.71 AUD
Jan 1, 2020
38.30 AUD
Jan 1, 2021
202.38 AUD
Jan 1, 2022
20.61 AUD
Jan 1, 2023
49.84 AUD
Jan 1, 2024
16.34 AUD
Jan 1, 2025
22.21 AUD
Jan 1, 2026
-20.14 AUD
The Dimerix P/B history
YEARP/BYoY
-20.14-190.67%
22.21+35.92%
16.34-67.21%
49.84+141.86%
20.61-89.82%
202.38+428.38%
38.30-45.83%
70.71+63.17%
43.34-61.66%
113.02-14.72%
132.52+23.83%
107.02-98.88%
9,520.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

P/B (Price-to-Book Ratio) of Dimerix is -20.14 in 2026.

P/B (Price-to-Book Ratio) of Dimerix changed from 22.21 to -20.14, representing a -190.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Dimerix since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Dimerix

All Key Metrics — Dimerix